Ozmosi | Otilonium bromide Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Otilonium bromide

Alternative Names: otilonium bromide, octylonium bromide, octylonium, Doralin
Clinical Status: Inactive
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | Bangladesh | Belgium | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Greece | Hong Kong | Hungary | India | Indonesia | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Menarini
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Spasm|Irritable Bowel Syndrome|Abdominal Pain

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12620000773932p

CUH_2009_VPA

N/A

Not yet recruiting

Other

None

2017-003258-18

The DOMINO trial: Diet Or Medication in Irritable bowel syNdrOme

P4

Completed

Irritable Bowel Syndrome|Spasm|Abdominal Pain

2019-11-14

2022-03-13

Treatments

NCT02576340

Randomized Prospective Trial

P4

Completed

Spasm

2013-05-01

2021-07-09

Primary Endpoints|Treatments

2005-001655-38

2005-001655-38

P4

Completed

Irritable Bowel Syndrome

2007-03-06

2022-03-12

Treatments